Ascletis Pharma Inc

Ascletis Pharma Inc a biotechnology company engages in the research and development manufacture marketing and sale of pharmaceutical products in Mainland China and internationally The company offers Ritonavir oral tablet a pharmacokinetic booster of various oral antiviral drugs targeting viral proteases and a component of the approved oral antiviral drug Paxlovid ASCLEVIR and GANOVO for the treatment of Hepatitis C virus It is also developing ASC22 for treating chronic hepatitis B CHB and human immunodeficiency virus functional cure ASC42 for chronic hepatitis B functional cure ASC10 and ASC11 to treat COVID19 ASC40 ASC41 ASC42 ASC43F FDC ASC44F FDC and ASC45F FDC for nonalcoholic steatohepatitis and ASC42 for the treatment of primary biliary cholangitis In addition the company is developing ASC40 to treat recurrent glioblastoma drug resistant breast cancer and KRAS mutant nonsmall cell lung cancer ASC61 and ASC63 for advanced solid tumors ASC60 to treat solid tumors and ASC40 for the treatment of acne Ascletis Pharma Inc was founded in 2013 and is headquartered in Hangzhou the Peoples Republic of China